Pelacarsen reduces the need for lipoprotein apheresis (LA) in patients with elevated Lp(a) and cardiovascular disease (CVD), according to results of the Phase 3 Lp(a)FRONTIERS APHERESIS trial carried out in Germany.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.